Lisa Alderson, Adela interim CEO
Labcorp backs Adela’s $48M Series A1 to advance methylation-based head and neck cancer test
Adela has raised $48 million in a Series A1 round backed by new investor and diagnostic giant Labcorp to fund a test for monitoring minimal …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
